Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Randomized, Dose-Escalation and Extension, Phase IA/IB Study to Evaluate Safety and Anti-Tumor Activity of RO7284755, A PD-1 Targeted IL-2 Variant (IL-2V) Immunocytokine, Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Conditions
Interventions
Eciskafusp Alfa
Atezolizumab
Locations
12
Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Herlev Hospital
Herlev, Denmark
Rigshospitalet
København Ø, Denmark
NKI/AvL
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Start Date
May 4, 2020
Primary Completion Date
October 2, 2025
Completion Date
October 2, 2025
Last Updated
April 1, 2026
NCT07489378
NCT07181681
NCT07360314
NCT07204340
NCT07403721
NCT06721689
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions